Walvax is engaged in research and development, manufacturing, and distribution of vaccines. The company focuses on producing safe and efficacious vaccines.

Walvax

Walvax | 799 followers on LinkedIn. Help everyone live a healthy life! | Founded in 2001, Walvax Biotechnology Co., Ltd. (Walvax) is a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe, efficacious and quality vaccines.

Headquartered in China’s southwestern city Kunming in Yunnan Province, Walvax went public via IPO in 2010 (300142.SZ) and started business expansion from traditional vaccines to innovative vaccines.

Director Of Research Development at Walvax Biotechnology Co., Ltd.

Xin Tong

HR at Walvax, a leading vaccine producer, engaged in research and development, manufacturing and distribution of safe, efficacious and quality…

Li Y.

Senior Specialist in Audit & Compliance at Walvax Biotech

Rick Zhang

Manager of Market Development and Management at Walvax Biotechnology Co., Ltd.

Huazhi Yang

🌿📊 Proud to announce exciting news in sustainable investing! In September 2024, MSCI upgraded Walvax Biotechnology's ESG rating to BBB, marking a significant milestone in our commitment to environmental, social, and governance practices. 👏 Key highlights from the report: Our Access to Health Care initiatives scored above the industry average, reflecting our dedication to improving global health outcomes. Product Safety & Quality also exceeded industry standards, underscoring our unwavering commitment to delivering safe, high-quality and efficacious vaccines to every corner of the world. This upgrade is a testament to the hard work and dedication of our entire team in integrating sustainability into our core business practices. At Walvax, we believe that responsible business practices go hand in hand with innovation in biotechnology. We remain committed to advancing both fronts as we work towards a healthier, more sustainable future. #ESG #SustainableInvesting #Biotechnology #HealthcareInnovation #CorporateResponsibility

Walvax will be exhibiting at CPHI Milan on October 8-10. If you're attending, we'd love to meet you at our booth (16G13). Come say hello and learn about our latest innovations in vaccine R&D and manufacturing! #CPHI2024 #WalvaxAtCPHI #Vaccines #Walvax

Exciting news! Our blockbuster product HPV-2 (Walrinvax™ ) has been pre-qualified by #WorldHealthOrganization . This achievement underscores our commitment to delivering safe, effective and high-quality vaccines to the world, further contributing to WHO's Global Strategy to Accelerate the Elimination of Cervical Cancer #Prequalification #HPV #CervicalCancer

Preserving our planet is a continuous journey. At #Walvax , we're taking steps to minimize our environmental footprint through eco-friendly practices and investments. While proud of our progress, we're driven to do more for a healthier planet. #EarthDay

Here are some highlights from our 2023 Annual Report. We were proud to be among the top 10 manufacturers by value (excluding COVID-19) 2022 in WHO's Global Vaccine Market Report 2023🎉🎉🎉 #WalvaxAnnualReport

At #Walvax , our passion for vaccines brings us together, as our name says it all: We All Love Vaccine X! Walvax produces efficacious, quality, innovative, and affordable products to protect people from the world’s deadliest diseases, and to help everyone live a healthy life!

Recently, our SARS-CoV-2 XBB.1.5 Variant mRNA Vaccine has been approved in China to prevent COVID-19 infection in individuals aged 18+, in line with WHO's recommendation on the use of the monovalent Omicron XBB.1.5 COVID-19 vaccines.

The first dose administered! We've initiated our #PCV13 non-inferiority & co-administration clinical trial with 2P+1 schedule in Indonesia, evaluating the immunogenicity and safety with EPI Vaccines.

Viewport Meta

IPhone / Mobile Compatible

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

Google Analytics

Content Delivery Network

Global Site Tag

Mobile Non Scaleable Content

Google Analytics 4

Yunchun Li

Yunhua Wang

Li Shi

Founder, CEO & Vice President

Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.

Investors Active in Gaithersburg, Maryland

Companies that Went Public in 2010

Asia Pharmaceutical Companies

Asia-Pacific (APAC) Biotechnology Public Companies

Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, is engaged in the research and development, production, and sale of bio-medicine products in the People’s Republic of China. It provides bio-medicines, such as vaccines, blood products, and others. The company offers Group A and C meningococcal polysaccharide vaccine for children and adults over the age of 2 years to prevent disease caused by the bacteria named neisseria meningitidis groups A and group C; and haemophilus influenzae type b conjugate vaccine for infants from the age of 2 months to 5 years to induce immunization against infectious diseases, such as meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis, etc. It also provides prefilled syringe dosage form of haemophilus influenzae type b conjugate vaccine; Group A, C meningococcal polysaccharide conjugate vaccine for infants from the age of 3 months to 5 years preventing diseases, such as cerebrospinal meningitis and septicemia; and Group ACYW135 meningococcal polysaccharide vaccine for children above 2 years old to prevent meningococcal disease caused by epidemic Neisseria meningitidis serogroups A, C, Y, and W-135. The company was founded in 2001 and is headquartered in Kunming, the People’s Republic of China.

Post-IPO Equity - Walvax Biotechnology

Kunming

Yunnan

China

Asia

Walvax Biotechnology

Global Meningococcal Vaccines Market To Reach $5.69 Billion By 2028 With A Growth Rate Of 9.6%

Walvax Biotechnology's H1 Net Profit Down 62.5% Y/Y

Sirnaomics nabs a major $105M funding round for next stage of its RNA work

Healthcare shares plunge over rabies vaccine scandal at Changsheng

Walvax Biotechnology Selects Medidata’s Cloud-Based Platform to Advance Pediatric Vaccine Program in China

Human Vaccine Market in China 2018 Forecasts (Hib, Human Rabies, Varicella, Influenza) Research Reports

Launched in 2020, this vaccine is for infants and children up to 5 years old to prevent diseases caused by 13 serotypes of pneumococcal bacteria.

Introduced in 2022, this vaccine is for females aged 9-30 to prevent diseases caused by HPV types 16 and 18, including cervical cancer.

Available since 2017, this vaccine targets individuals over 2 years old to prevent diseases from 23 pneumococcal serotypes.

Since 2007, this vaccine is for infants and children up to 5 years old to prevent diseases caused by Haemophilus influenzae type b.

Launched in 2009, this vaccine is for infants and children up to 5 years old to prevent diseases caused by A and C meningococcal bacteria.

Since 2012, this vaccine is for individuals over 2 years old to prevent diseases caused by ACYW135 meningococcal bacteria.

news impact assignment basic	general
public peers	general	Nov 17, 2024 8:44 PM	81b0a6af
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 17, 2024 8:44 PM	66a8986d
crunchbase trigger	general	Nov 17, 2024 8:44 PM	f9ca60ca
crunchbase profile	general	Nov 17, 2024 9:05 PM	328a052f
li profile	general	Nov 17, 2024 8:44 PM	1ec06aa8
translate crunchbase fundingrounds	general	Nov 17, 2024 9:30 PM	6ba7ecb0
peers	general	Nov 17, 2024 8:44 PM	90f7ff34
news basic	general	Nov 17, 2024 8:44 PM	5625fab7
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

WALV

COM:WALVAX:EN

Walvax